Listar02.02.01. Investigación y comunicación científica por tema "Depressive Disorder, Treatment-Resistant/drug therapy/blood/pathology/diagnostic imaging"

Mostrando ítems 1-1 de 1

Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study

Rodríguez-Lorente, Ana; Campos-Navarro, María-Pilar; Gil-Montoya, Ángela; Marín-Pérez, Celia; Masó-Navarro, María-Luisa; Orgaz-Morales, Manuel-Tomás; López-Ramírez, Nuria; García-Carmona, Juan-Antonio (CAMBRIDGE UNIV PRESS, 2025)

OBJECTIVES: This proof-of-concept study aimed to assess the impact of intranasal esketamine (ESK-IN) in brain volume and neurofilament light chain (sNfL) over 6-months in patients with treatment resistant depression (TDR). ...

Mostrando ítems 1-1 de 1

Buscar en DSpace